Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. director Thomas J. Lynch Jr. received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, conditioned on his continued service on the board of directors, and expire on June 23, 2036. Following this grant, he holds options for 28,000 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lynch Thomas J. Jr.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 28,000 options Exercise price: $4.08 per share Underlying shares: 28,000 shares +2 more

5 metrics

Options granted 28,000 options Stock options to buy common stock granted to director

Exercise price $4.08 per share Exercise price for newly granted stock options

Underlying shares 28,000 shares Common shares underlying the options

Expiration date June 23, 2036 Option expiration for this grant

Post-grant option holdings 28,000 options Total derivative securities held after the transaction

Key Terms

Stock Options (Right to buy), grant/award acquisition, vests in full, derivative securities

4 terms

Stock Options (Right to buy) financial

"security_title: Stock Options (Right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

vests in full financial

"The option vests in full on the first anniversary of the grant date"

derivative securities financial

"derivativeTransactionCount: 1 derivative-type record reported"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:07 PM Accepted by SEC EDGAR 06/25/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lynch Thomas J. Jr.

(Last) (First) (Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		(1)	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Thomas J. Lynch Jr.	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Foghorn Therapeutics (FHTX) director Thomas J. Lynch Jr. receive in this Form 4?

Thomas J. Lynch Jr. received a grant of stock options for 28,000 Foghorn Therapeutics common shares at an exercise price of $4.08 per share. This is a compensation-related award, not an open-market stock purchase.

What is the exercise price and expiration date of the new FHTX stock options?

The stock options granted to Thomas J. Lynch Jr. have an exercise price of $4.08 per share and an expiration date of June 23, 2036. He can only benefit if the stock trades above the exercise price before expiration.

When do Thomas J. Lynch Jr.’s newly granted FHTX options vest?

The options vest in full on the first anniversary of the grant date, subject to his continued service on Foghorn Therapeutics’ board. If he stops serving before that anniversary, the vesting conditions in the award agreement would apply.

How many Foghorn Therapeutics shares are covered by Thomas J. Lynch Jr.’s options after this filing?

After this grant, Thomas J. Lynch Jr. holds stock options covering 28,000 shares of Foghorn Therapeutics common stock. The Form 4 shows this entire position as directly owned derivative securities rather than outright common shares.

Does this FHTX Form 4 show an insider buying or selling shares in the market?

No, the Form 4 reports a grant of stock options as compensation, not a market buy or sell. The transaction is coded as an acquisition (A) of derivative securities with no open-market trading activity disclosed.